NASDAQ:RVMD

Revolution Medicines News Headlines

$42.67
-2.35 (-5.22 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$42.52
Now: $42.67
$45.64
50-Day Range
$41.28
MA: $45.83
$49.54
52-Week Range
$20.53
Now: $42.67
$56.18
Volume645,521 shs
Average Volume573,372 shs
Market Capitalization$3.13 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Revolution Medicines (NASDAQ RVMD) News Headlines Today

SourceHeadline
Zacks Investment Research Upgrades Revolution Medicines (NASDAQ:RVMD) to "Hold"Zacks Investment Research Upgrades Revolution Medicines (NASDAQ:RVMD) to "Hold"
marketbeat.com - March 25 at 2:55 AM
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 18,215 Shares of StockInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 18,215 Shares of Stock
americanbankingnews.com - April 7 at 7:32 PM
Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells $1,274,656.80 in StockRevolution Medicines, Inc. (NASDAQ:RVMD) Director Sells $1,274,656.80 in Stock
americanbankingnews.com - April 7 at 7:32 PM
iShares MSCI India ETF (INDA.MX)iShares MSCI India ETF (INDA.MX)
in.finance.yahoo.com - April 6 at 8:40 AM
This 2020 Biotech IPO Is Poised to Break Out in 2021This 2020 Biotech IPO Is Poised to Break Out in 2021
finance.yahoo.com - April 2 at 7:49 AM
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
finance.yahoo.com - March 11 at 7:59 PM
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor ConferencesRevolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
finance.yahoo.com - February 18 at 9:45 AM
Estimating The Fair Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)Estimating The Fair Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)
finance.yahoo.com - February 9 at 3:06 PM
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of  Underwriters Option to Purchase Additional SharesRevolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - February 8 at 6:20 PM
Revolution Medicines Raises $260.9 Million In Upsized OfferingRevolution Medicines Raises $260.9 Million In Upsized Offering
finance.yahoo.com - February 4 at 1:52 PM
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common StockRevolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
finance.yahoo.com - February 4 at 12:14 AM
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare ConferenceRevolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 9:25 AM
Is RVMD A Good Stock To Buy Now?Is RVMD A Good Stock To Buy Now?
finance.yahoo.com - December 15 at 11:50 PM
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business GrowthWe Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
finance.yahoo.com - November 26 at 12:37 PM
Why Revolution Medicines Stock Is Trading HigherWhy Revolution Medicines Stock Is Trading Higher
benzinga.com - November 12 at 7:57 PM
Revolution Medicines EPS misses by $0.03, misses on revenueRevolution Medicines EPS misses by $0.03, misses on revenue
seekingalpha.com - November 12 at 9:52 AM
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate ProgressRevolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
finance.yahoo.com - November 12 at 9:52 AM
Revolution Medicines RMC-4630 shows anti-tumor activity in colorectal cancer; collaborates with AstraZenecaRevolution Medicines' RMC-4630 shows anti-tumor activity in colorectal cancer; collaborates with AstraZeneca
seekingalpha.com - October 26 at 3:17 AM
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted CancersRevolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
finance.yahoo.com - October 24 at 12:45 PM
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib forRevolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for
bloomberg.com - October 14 at 1:55 PM
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid TumorsRevolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
finance.yahoo.com - October 14 at 2:58 AM
Revolution Medicines to present interim data from early-stage cancer study in an upcoming symposiumRevolution Medicines to present interim data from early-stage cancer study in an upcoming symposium
seekingalpha.com - October 12 at 4:39 PM
Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in SessionRevolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session
nasdaq.com - September 22 at 2:05 PM
High Hopes for Amgen and Gilead at Europe’s Biggest Cancer Research ConferenceHigh Hopes for Amgen and Gilead at Europe’s Biggest Cancer Research Conference
finance.yahoo.com - September 18 at 6:05 PM
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) InhibitorsRevolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
finance.yahoo.com - September 16 at 1:36 PM
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceRevolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 9 at 10:24 AM
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development ConferenceRevolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
finance.yahoo.com - September 8 at 8:15 AM
Heres What Revolution Medicines, Inc.s (NASDAQ:RVMD) Shareholder Ownership Structure Looks LikeHere's What Revolution Medicines, Inc.'s (NASDAQ:RVMD) Shareholder Ownership Structure Looks Like
finance.yahoo.com - August 28 at 12:42 PM
Here's What Revolution Medicines, Inc.'s (NASDAQ:RVMD) Shareholder Ownership Structure Looks LikeHere's What Revolution Medicines, Inc.'s (NASDAQ:RVMD) Shareholder Ownership Structure Looks Like
finance.yahoo.com - August 28 at 12:42 PM
Revolution Medicines, Inc. (RVMD)Revolution Medicines, Inc. (RVMD)
ca.finance.yahoo.com - August 16 at 7:22 AM
Revolution Medicines Inc.Revolution Medicines Inc.
barrons.com - August 16 at 7:22 AM
Revolution Medicines IncRevolution Medicines Inc
reuters.com - August 12 at 9:39 AM
Revolution Medicines EPS misses by $0.10, misses on revenueRevolution Medicines EPS misses by $0.10, misses on revenue
seekingalpha.com - August 10 at 5:48 PM
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate ProgressRevolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
finance.yahoo.com - August 10 at 7:47 AM
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesRevolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - July 13 at 9:26 PM
Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2%Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2%
finance.yahoo.com - July 13 at 10:00 AM
Revolution Medicines Announces Proposed Public Offering of Common StockRevolution Medicines Announces Proposed Public Offering of Common Stock
finance.yahoo.com - July 6 at 8:02 PM
Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel CoronavirusRevolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus
finance.yahoo.com - June 30 at 5:47 PM
Hedge Funds Are Cashing Out Of Innovative Industrial Properties, Inc. (IIPR)Hedge Funds Are Cashing Out Of Innovative Industrial Properties, Inc. (IIPR)
finance.yahoo.com - June 28 at 6:07 PM
Hedge Funds Are Piling Into Avanos Medical (AVNS)Hedge Funds Are Piling Into Avanos Medical (AVNS)
finance.yahoo.com - June 28 at 6:07 PM
Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer TherapiesRevolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies
finance.yahoo.com - June 22 at 7:27 PM
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 InhibitorRevolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
finance.yahoo.com - June 22 at 9:25 AM
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
finance.yahoo.com - June 9 at 10:07 AM
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate ProgressRevolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
finance.yahoo.com - May 14 at 5:52 PM
Bill.com Holdings, Inc. (BILL) Q3 2020 Earnings Call TranscriptBill.com Holdings, Inc. (BILL) Q3 2020 Earnings Call Transcript
www.fool.com - May 8 at 2:23 PM
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer ModelsRevolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
finance.yahoo.com - April 29 at 10:53 AM
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer InstituteNew Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
finance.yahoo.com - March 9 at 8:20 AM
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional SharesRevolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
www.marketwatch.com - February 20 at 8:42 PM
Revolution Medicines shares soar 85% in trading debut after IPO priced at top end of rangeRevolution Medicines shares soar 85% in trading debut after IPO priced at top end of range
finance.yahoo.com - February 20 at 10:40 AM
The Funded: 7 Bay Area startups raise over $135M at week's endThe Funded: 7 Bay Area startups raise over $135M at week's end
finance.yahoo.com - February 20 at 10:40 AM
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesRevolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - February 20 at 10:40 AM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.